ST Germain D J Co. Inc. Sells 896 Shares of Novo Nordisk A/S (NYSE:NVO)

ST Germain D J Co. Inc. lessened its stake in Novo Nordisk A/S (NYSE:NVO) by 1.1% in the 4th quarter, Holdings Channel.com reports. The firm owned 79,961 shares of the company’s stock after selling 896 shares during the quarter. ST Germain D J Co. Inc.’s holdings in Novo Nordisk A/S were worth $6,878,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Strategic Investment Solutions Inc. IL purchased a new position in Novo Nordisk A/S in the second quarter worth about $25,000. Abound Wealth Management increased its position in shares of Novo Nordisk A/S by 257.4% during the second quarter. Abound Wealth Management now owns 218 shares of the company’s stock valued at $31,000 after acquiring an additional 157 shares in the last quarter. Daiwa Securities Group Inc. purchased a new stake in Novo Nordisk A/S during the 3rd quarter valued at $28,000. Capital Performance Advisors LLP bought a new stake in shares of Novo Nordisk A/S in the 3rd quarter worth $42,000. Finally, Carolina Wealth Advisors LLC purchased a new position in shares of Novo Nordisk A/S in the third quarter worth $48,000. Institutional investors own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have issued reports on NVO. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday. StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. Finally, UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Novo Nordisk A/S has a consensus rating of “Buy” and an average target price of $140.20.

Novo Nordisk A/S Stock Performance

Shares of NYSE:NVO traded up $0.91 during mid-day trading on Friday, reaching $86.55. 2,646,449 shares of the company traded hands, compared to its average volume of 6,717,778. The company’s 50 day moving average price is $100.86 and its 200-day moving average price is $119.79. The firm has a market cap of $388.40 billion, a PE ratio of 28.01, a PEG ratio of 1.37 and a beta of 0.45. Novo Nordisk A/S has a 52 week low of $81.50 and a 52 week high of $148.15. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.